Artelo Biosciences' ART26.12 Shows Promise for Spinal Cord Injury Pain in New Preclinical Data
ARTL is trading near its 52-week low of $1.03 (13% above the low) on light trading volume (0.2× avg).
Summary
Artelo Biosciences announced positive nonclinical data for its lead drug candidate, ART26.12, demonstrating its potential to alleviate neuropathic pain associated with spinal cord injury in animal models. This expands the potential market for ART26.12 as a first-in-class, non-opioid therapy for a significant unmet medical need. The positive pipeline development offers a counterpoint to the company's recent financial challenges, which include ongoing going concern warnings and significant potential dilution from recent and proposed capital raises.
At the time of this announcement, ARTL was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.03 to $85.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.